EY refers to the global organization, and may refer to one or more, of the member firms of Ernst & Young Global Limited, each of which is a separate legal entity. Ernst & Young Global Limited, a UK company limited by guarantee, does not provide services to clients.
Recent Searches
Life Sciences
Our Global Life Sciences sector can help you navigate forward and achieve sustainable success in the new health-outcomes-driven ecosystem.
Our latest thinking
EY Biotech Beyond Borders Report 2025
Biotech companies and life sciences leaders are managing uncertainty and preparing to bounce back across the biotechnology landscape. Find out how.
The Unstoppables: Success stories of the world’s most inspiring entrepreneurs
The latest EY entrepreneurship documentary, “The Unstoppables 3,” features inspiring professional and personal entrepreneur success stories. Read more.
Pulse of the MedTech Industry Report
EY MedTech report on dealmaking, financing and state of the industry, with insights on growth and commercial strategies, AI, consumer and more.
How will you respond to clinicians sounding the alarm on unsustainable care delivery models?
The EY Global Voices in Health Care Study finds health systems must embrace sustainable care delivery models to address workforce challenges. Learn more.
How life sciences businesses transform the tax and finance function
Life sciences organizations operate in a complex industry – one that looks set to become more challenging, including from a tax perspective. Learn more.
How CDMOs are leading innovation for pharmaceutical partners
Discover how CDMO M&A trends show CDMOs are becoming emerging technology leaders for pharmaceutical partners.
What going digital means for Takeda
Find out how Takeda Business Solutions (TBS) fast-tracked its digitalization evolution.
How to navigate global TP controversy in life sciences — Asia-Pacific and Europe focus
In this webcast, panelists discuss life sciences transfer pricing controversy trends and developments in Asia-Pacific and Europe. Learn more.
How to navigate global TP controversy in life sciences — US focus
In this webcast, panelists discuss life sciences transfer pricing controversy trends and developments in the US. Learn more.
How ecosystem participation drives more value for life sciences deals
Biopharmas need to embrace strategic partnerships that share risk and reward to achieve their growth ambitions. Learn more.
How to account for outcome-based payment arrangements in life sciences
The use of outcome-based payment arrangements in the life sciences sector is growing in many jurisdictions, especially across Europe.
How the future of health care is becoming a reality
Human-centric care will soon become a reality, driven by data and technology.
Five trends redefining the health sciences and wellness operating model
As demand from consumers accelerates the adoption of new technologies, we explore how companies can provide a more convenient health experience.
Optimizing health outcomes for all
Discover key insights that highlight strategic priorities and investments to enhance care across sectors, along with the evolution of organizational capabilities, based on a survey of 500 industry leaders.
How AI can support decision-making in drug development portfolios
For the pharmaceutical industry, AI can be a powerful tool to drive better-informed asset portfolio decisions.
How EY can help
-
The EY Promotional Content Management Services team can provide you with support that will transform your processes and improve your results. Learn more.
Read more -
The EY Smart Reviewer can help your business accelerate and optimize the review and approval process for marketing and promotional materials. Find out how.
Read more -
Our Biopharma Launch Edge team can help your business achieve successful launches. Find out how.
Read more -
The EY Health Outcomes Platform aligns all stakeholders by providing a practical solution to operate value-based contracts at scale. Find out how.
Read more - Read more
-
Our Healthcare Strategy Consulting teams help organizations develop digital, transaction and value strategies to build resilience and drive future growth
Read more
Direct to your inbox
Stay up to date with our Editor's picks newsletter.
Case studies
How tech and trust transformed a tax operating model
Global pharmaceutical player Boehringer Ingelheim is reimaging its tax operating model to boost quality and efficiency. Learn more in this case study.